Aspirin for the primary prevention of cardiovascular events: Recommendations and rationale

American Family Physician

Volumn 65, Issue 10, 2002, Pages 2107-2110

  Berg, Alfred O ^a  

^a AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

CARDIOVASCULAR DISEASE; CHEMOPROPHYLAXIS; HUMAN; PREVENTIVE HEALTH SERVICE; PRIMARY PREVENTION; REVIEW; UNITED STATES;

ADULT; AGED; ASPIRIN; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS;

EID: 0037093445     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Prediction of coronary heart disease using risk factor categories
2. Deaths: Final data for 1997
3. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
4. Final report on the aspirin component of the ongoing Physicians' Health Study
5. Randomised trial of prophylactic daily aspirin in British male doctors
6. Thrombosis prevention trial: Randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk
7. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
8. Low-dose aspirin and vitamin E in people at cardiovascular risk: A randomised trial in general practice
9. The gastrointestinal toxicity of aspirin: An overview of randomised controlled trials
10. Aspirin: Benefit and risk in thromboprophylaxis
11. Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events
12. Acetylsalicylic acid and the primary prevention of cardiovascular disease
13. Aspirin therapy in diabetes
14. Aspirin as a therapeutic agent in cardiovascular disease: A statement for healthcare professionals from the American Heart Association
15. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention